Research with Dr. SanaChildren's health research, explained
Research programme

SSPE Research

Our working notebook on subacute sclerosing panencephalitis — the ideas we are working from, what we have built so far, and what is new in the literature.

Dr. Sana Fatima Updated 15 November 2026Draft · awaiting Dr. Sana's medical review
A reading of the published literature, not a clinical guideline. Every claim below is sourced, and each source is marked with how it was actually obtained — a claim resting on an abstract alone says so. Treatment decisions belong to the clinician in front of the patient.

Where the research stands

SSPE has no proven treatment. No regimen has shown benefit in a well-run randomised trial, the trial registries are almost empty, and most of what is repeated about treatment rests on small, uncontrolled series. At the same time, the measles waves of 2025–2026 mean more children will develop SSPE over the coming decade, and Pakistan is seeing more cases than any single registry has ever captured.

This page collects the concepts our work is built on, the pieces we have finished, and what has been published since. It is a reading of the literature, not a clinical guideline.

Key concepts

A virus that never leaves the brain

In SSPE, measles virus survives in brain cells as a damaged, mutated population that can no longer make free virus particles. Instead it passes directly from cell to cell, slowly, over years 11Yousaf I, Hannon WW, Donohue RC, et al. (Cattaneo group) 2023, PLoS Pathogens 19(12):e1011817, PMID 38127684full text. Mapping one patient's brain showed two virus sub-populations spread through every region sampled 1.

Why antibodies do not stop it

Children with SSPE have very high measles antibody levels in their spinal fluid, yet the disease still progresses (PLoS ONE 2018). A virus that moves from cell to cell is largely out of the antibodies' reach. The same high antibody level is what makes the spinal-fluid test so useful for diagnosis.

The best trial evidence is negative

The only large randomised trial, 121 patients across several countries, found that adding interferon to oral isoprinosine gave no extra benefit — about a third did well in both groups 22Gascon GG, international SSPE consortium randomised trial, 2003, PubMed 14736075abstract only. A later placebo-controlled trial of aprepitant was also negative 33Oncel I et al. 2020, aprepitant double-blind placebo-controlled SSPE trial, PMID 32718528full text. Japan's 2026 national guideline is the only formally graded guideline in existence 44SSPE Clinical Practice Guideline 2026, MHLW Prion and Slow-Virus Infection Research Group, March 2026 (CQ7-2, CQ11)full text.

Plateaus can look like treatment working

A small share of patients stabilise or improve on their own for a time, and remissions are usually temporary. A 2026 review of 77 long-term survivors found that 62% first stabilised, but only 42% were still doing well at last follow-up, and long survival may reflect the disease's own course as much as treatment 55Garg RK, Pandey S, Rizvi I, Singhal S. 2026, Encephalitis 6(4):91-102full text. Any uncontrolled report has to be read against this.

Japan's antiviral programme

Japan ran the world's only systematic antiviral programme for SSPE, measuring drug levels in the spinal fluid 66Hashimoto K & Hosoya M 2021, SSPE treatment review (Fukushima Medical University), PMC7830519full text. It produced the field's only signal that response tracks the drug level reached 77Hosoya M, et al. 2004, Antimicrob Agents Chemother 48(12):4631-4635, Introduction, PMC529186full text, but the series are small, uncontrolled, and their response rates shrank as more patients were included.

The new drug pipeline

A new oral measles drug, GHP-88310, protects animals and blocks transmission, and its developers are preparing it for human testing — but there are no data yet on infection inside the brain 88Lieber et al., Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models, Science Advances 12:eaef1594, 2026full text. Fusion-inhibitor peptides improved survival in a true SSPE mouse model, but only when given directly into the brain 99PLoS ONE 2016, DOI 10.1371/journal.pone.0162823, PMC5017735 (fusion-inhibitory peptide in an authentic SSPE mouse model)full text. Across the pipeline, getting a drug into the brain is the binding problem, not potency.

No animal model

The years-long silent incubation means there is no good animal model of SSPE, which slows every drug programme 1.

Pakistan has the patients, but no registry

One Peshawar clinic reported 90 confirmed cases in the year to September 2026 1010Gavi VaccinesWork, 15 Oct 2026 (Dr Khalili, private facility, Peshawar)secondary, against an international registry that captured nine patients across four countries in three years 1111Öncel I, Kravljanac R, Jaxybayeva A, Bakhtadze S, Wilmshurst J, Wirrell E, Anlar B, ICNC e-poster 624full text. A call for a global SSPE registry was published in 2026 1212Gilboa 2026, published call for a global SSPE registry, PMID 42791058abstract only. A registry needs no new drug and no new science, and it is the piece of this work that can start now.

The trial landscape is almost empty

Seven SSPE studies are registered worldwide, and none of the landmark trials was registered 1313WHO ICTRP, "subacute sclerosing panencephalitis", 7 records for 7 trials, queried 8 Nov 2026record. The only SSPE study on ClinicalTrials.gov is a ketogenic diet study from Aga Khan University, Karachi, with no posted results 1414NCT05152771, Role of Ketogenic Diet in SSPE, Aga Khan University, ClinicalTrials.govrecord.

Our work

  • Done · 8 Nov 2026
    SSPE for parents: what SSPE is, early signs, diagnosis and prevention, with every fact sourced.
  • Done · 8 Nov 2026
    Source map: all 85 documents behind the research, each tagged by whether we read the full paper or only the abstract.
  • Done · 8 Nov 2026
    Registry and regulation: what a Pakistani SSPE registry should record, which partners to approach, and the regulatory route.
  • Weekly
    Literature check: every week we ask Europe PMC what is new on SSPE and measles antivirals. New papers go on the reading list below until someone has read them.
  • In progress
    What each group achieved: Japan, Türkiye, India, the Philippines and Pakistan, described from the published work.
  • Next
    Graded evidence tiers: how strong the evidence is for each approach used today. It goes live only after Dr. Sana's review.
  • On request
    The research also looks at treatment combinations that have never been tried together. These are not published here; clinicians and researchers can request them.

Latest news and updates

  • · ResearchEvery SSPE source now says how it was obtained

    We published the full source list behind the SSPE research — 85 documents, each tagged by whether we read the full paper or could only get the abstract. 51 were read in full.

  • · CorrectionCorrection: the Peshawar case count

    We had written that one Peshawar clinic confirmed 90 SSPE cases "in the first nine months of 2026". The original report says 90 confirmed cases in the year to September 2026 — twelve months, not nine. Corrected everywhere it appeared.

  • · CorrectionCorrection: what the new measles antiviral can and cannot show

    We had said the experimental oral measles drug GHP-88310 has "no brain data". That was too strong. The paper does report brain tissue drug concentrations, from a single-dose study in cotton rats. What it has no data on is whether the drug does anything to an infection *inside* the brain — there is no CNS infection model anywhere in the programme.

  • · MethodA weekly check for new SSPE research

    Every week we now ask Europe PMC what has been published on SSPE and on measles antivirals, and compare it against what this site already cites. The first run looked back 120 days and found 18 papers we had not seen, including a study of SSPE following measles outbreaks in the Philippines and new antibodies against the measles fusion protein.

Every update and correction →

New papers on the reading list

The last check found nothing new.

Get involved

If you are a clinician or researcher working on SSPE, or a family who would like to support a registry in Pakistan, message us on Instagram. We are especially keen to hear from paediatric neurology units in Khyber Pakhtunkhwa, and from anyone already collecting SSPE cases.

Sources

  1. 1.Yousaf I, Hannon WW, Donohue RC, et al. (Cattaneo group) 2023, PLoS Pathogens 19(12):e1011817, PMID 38127684full text
    pmc.ncbi.nlm.nih.gov/articles/PMC10735034
  2. 2.Gascon GG, international SSPE consortium randomised trial, 2003, PubMed 14736075abstract only
    pubmed.ncbi.nlm.nih.gov/14736075
  3. 3.Oncel I et al. 2020, aprepitant double-blind placebo-controlled SSPE trial, PMID 32718528full text
    openaccess.marmara.edu.tr/entities/publication/b0fd569e-9852-408d-bfe5-daeee2fa6c90/full
  4. 4.SSPE Clinical Practice Guideline 2026, MHLW Prion and Slow-Virus Infection Research Group, March 2026 (CQ7-2, CQ11)full text
    prion.umin.jp/guideline/pdf/guideline_SSPE_2026.pdf
  5. 5.Garg RK, Pandey S, Rizvi I, Singhal S. 2026, Encephalitis 6(4):91-102full text
    www.encephalitisjournal.org/journal/view.php?doi=10.47936%2Fencephalitis.2026.00108
  6. 6.Hashimoto K & Hosoya M 2021, SSPE treatment review (Fukushima Medical University), PMC7830519full text
    pmc.ncbi.nlm.nih.gov/articles/PMC7830519
  7. 7.Hosoya M, et al. 2004, Antimicrob Agents Chemother 48(12):4631-4635, Introduction, PMC529186full text
    pmc.ncbi.nlm.nih.gov/articles/PMC529186
  8. 8.Lieber et al., Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models, Science Advances 12:eaef1594, 2026full text
    pmc.ncbi.nlm.nih.gov/articles/PMC13196758
  9. 9.PLoS ONE 2016, DOI 10.1371/journal.pone.0162823, PMC5017735 (fusion-inhibitory peptide in an authentic SSPE mouse model)full text
    pmc.ncbi.nlm.nih.gov/articles/PMC5017735
  10. 10.Gavi VaccinesWork, 15 Oct 2026 (Dr Khalili, private facility, Peshawar)secondary
    www.gavi.org/vaccineswork/doctors-say-rare-fatal-measles-linked-condition-rising-pakistan
  11. 11.Öncel I, Kravljanac R, Jaxybayeva A, Bakhtadze S, Wilmshurst J, Wirrell E, Anlar B, ICNC e-poster 624full text
    icnapedia.org/eposters/624
  12. 12.Gilboa 2026, published call for a global SSPE registry, PMID 42791058abstract only
    pubmed.ncbi.nlm.nih.gov/42791058
  13. 13.WHO ICTRP, "subacute sclerosing panencephalitis", 7 records for 7 trials, queried 8 Nov 2026record
    trialsearch.who.int
  14. 14.NCT05152771, Role of Ketogenic Diet in SSPE, Aga Khan University, ClinicalTrials.govrecord
    clinicaltrials.gov/study/NCT05152771